|
1
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wells A, Chao YL, Grahovac J, Wu Q and
Lauffenburger DA: Epithelial and mesenchymal phenotypic switchings
modulate cell motility in metastasis. Front Biosci (Landmark Ed).
16:815–837. 2011. View
Article : Google Scholar
|
|
3
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen KC, Sung PL, Yen MS, Chuang CM, Liou
WS and Wang PH: MicroRNAs regulate several functions of normal
tissues and malignancies. Taiwan J Obstet Gynecol. 52:465–469.
2013. View Article : Google Scholar
|
|
8
|
Olson P, Lu J, Zhang H, Shai A, Chun MG,
Wang Y, Libutti SK, Nakakura EK, Golub TR and Hanahan D: MicroRNA
dynamics in the stages of tumorigenesis correlate with hallmark
capabilities of cancer. Genes Dev. 23:2152–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farazi TA, Horlings HM, Ten Hoeve JJ,
Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F,
van Kouwenhove M, et al: MicroRNA sequence and expression analysis
in breast tumors by deep sequencing. Cancer Res. 71:4443–4453.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, Shi
L, Liu N, Wang G, Pu P, You Y, et al: Reduction of miR-21 induces
glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep.
24:195–201. 2010.PubMed/NCBI
|
|
11
|
Zhang HH, Qi F, Cao YH, Zu XB and Chen MF:
Expression and clinical significance of microRNA-21, maspin and
vascular endothelial growth factor-C in bladder cancer. Oncol Lett.
10:2610–2616. 2015.PubMed/NCBI
|
|
12
|
Fukushima Y, Iinuma H, Tsukamoto M,
Matsuda K and Hashiguchi Y: Clinical significance of microRNA-21 as
a biomarker in each Dukes' stage of colorectal cancer. Oncol Rep.
33:573–582. 2015.
|
|
13
|
Zhou X, Ren Y, Moore L, Mei M, You Y, Xu
P, Wang B, Wang G, Jia Z, Pu P, et al: Downregulation of miR-21
inhibits EGFR pathway and suppresses the growth of human
glioblastoma cells independent of PTEN status. Lab Invest.
90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kothari AN, Mi Z, Zapf M and Kuo PC: Novel
clinical therapeutics targeting the epithelial to mesenchymal
transition. Clin Transl Med. 3:352014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad
A, Banerjee S, Azmi AS, Miele L and Sarkar FH: Notch-1 induces
epithelial-mesenchymal transition consistent with cancer stem cell
phenotype in pancreatic cancer cells. Cancer Lett. 307:26–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Braun J, Hoang-Vu C, Dralle H and
Hüttelmaier S: Down-regulation of microRNAs directs the EMT and
invasive potential of anaplastic thyroid carcinomas. Oncogene.
29:4237–4244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kumarswamy R, Volkmann I, Jazbutyte V,
Dangwal S, Park DH and Thum T: Transforming growth factor-β-induced
endothelial-to-mesenchymal transition is partly mediated by
microRNA-21. Arterioscler Thromb Vasc Biol. 32:361–369. 2012.
View Article : Google Scholar
|
|
18
|
Weng LP, Smith WM, Brown JL and Eng C:
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell
growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos
complex formation in a breast cancer model. Hum Mol Genet.
10:605–616. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y,
Zhao L, Qu H, Fan Y and Wu C: Antagonism of miR-21 reverses
epithelial-mesenchymal transition and cancer stem cell phenotype
through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One.
7:e395202012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J and Zhou BP: Activation of β-catenin
and Akt pathways by Twist are critical for the maintenance of EMT
associated cancer stem cell-like characters. BMC Cancer. 11:492011.
View Article : Google Scholar
|
|
21
|
Iliopoulos D, Polytarchou C,
Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K and Tsichlis
PN: MicroRNAs differentially regulated by Akt isoforms control EMT
and stem cell renewal in cancer cells. Sci Signal. 2:ra622009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Irie HY, Pearline RV, Grueneberg D, Hsia
M, Ravichandran P, Kothari N, Natesan S and Brugge JS: Distinct
roles of Akt1 and Akt2 in regulating cell migration and
epithelial-mesenchymal transition. J Cell Biol. 171:1023–1034.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan LX, Liu YH, Xiang JW, Wu QN, Xu LB,
Luo XL, Zhu XL, Liu C, Xu FP, Luo DL, et al: PIK3R1 targeting by
miR-21 suppresses tumor cell migration and invasion by reducing
PI3K/AKT signaling and reversing EMT, and predicts clinical outcome
of breast cancer. Int J Oncol. 48:471–484. 2016.
|
|
24
|
Liu Z, Jin ZY, Liu CH, Xie F, Lin XS and
Huang Q: MicroRNA-21 regulates biological behavior by inducing EMT
in human cholangiocarcinoma. Int J Clin Exp Pathol. 8:4684–4694.
2015.PubMed/NCBI
|
|
25
|
Tiwari N, Meyer-Schaller N, Arnold P,
Antoniadis H, Pachkov M, van Nimwegen E and Christofori G: Klf4 is
a transcriptional regulator of genes critical for EMT, including
Jnk1 (Mapk8). PLoS One. 8:e573292013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng G, Li N, Jia X, Peng C, Luo L, Deng
Y, Yin J, Song Y, Liu H, Lu M, et al: MYCN-mediated miR-21
overexpression enhances chemo-resistance via targeting CADM1 in
tongue cancer. J Mol Med (Berl). 94:1129–1141. 2016. View Article : Google Scholar
|
|
27
|
Huang Q, Liu L, Liu CH, You H, Shao F, Xie
F, Lin XS, Hu SY and Zhang CH: MicroRNA-21 regulates the invasion
and metastasis in cholangiocarcinoma and may be a potential
biomarker for cancer prognosis. Asian Pac J Cancer Prev.
14:829–834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu CZ, Liu W, Zheng Y, Su JM, Li JJ, Yu
L, He XD and Chen SS: PTEN and PDCD4 are bona fide targets of
microRNA-21 in human cholangiocarcinoma. Chin Med Sci J. 27:65–72.
2012.PubMed/NCBI
|
|
29
|
Selaru FM, Olaru AV, Kan T, David S, Cheng
Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, et al: MicroRNA-21 is
overexpressed in human cholangiocarcinoma and regulates programmed
cell death 4 and tissue inhibitor of metalloproteinase 3.
Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bao B, Ali S, Kong D, Sarkar SH, Wang Z,
Banerjee S, Aboukameel A, Padhye S, Philip PA and Sarkar FH:
Anti-tumor activity of a novel compound-CDF is mediated by
regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS
One. 6:e178502011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Latifi A, Abubaker K, Castrechini N, Ward
AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay
JK, et al: Cisplatin treatment of primary and metastatic epithelial
ovarian carcinomas generates residual cells with mesenchymal stem
cell-like profile. J Cell Biochem. 112:2850–2864. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG,
Zheng S and Huang J: Activation of Akt and MAPK pathways enhances
the tumorigenicity of CD133+ primary colon cancer cells.
Carcinogenesis. 31:1376–1380. 2010. View Article : Google Scholar : PubMed/NCBI
|
